Hospitals
Singapore has 20 acute hospitals, one psychiatric hospital and 10 community hospitals.
Description
Singapore has solidified its position as the premier biomedical sciences hub in Asia, offering a sophisticated ecosystem that seamlessly bridges translational research and commercialization.
The nation is globally renowned for its world-class biopharmaceutical manufacturing capabilities, hosting the regional headquarters and state-of-the-art facilities of industry giants like GSK, Pfizer and Roche. In the biotechnology sector, Singapore excels in high-growth modalities, including cell and gene therapy (CGT), mRNA therapeutics and antibody-drug conjugates (ADCs), supported by specialized infrastructure like Biopolis.
The medical device industry is equally robust, with Singapore being the first to achieve the highest WHO maturity level (ML4) for medtech regulation, ensuring rigorous safety standards for innovative diagnostics and AI-enabled devices.
The city-state’s healthcare innovation is driven by the Research, Innovation and Enterprise (RIE) 2030 plan, which funnels billions into precision medicine, digital health and sustainable manufacturing. Leading academic research institutions, such as A*STAR and the National University Health System (NUHS), foster a collaborative environment where public-private partnerships flourish.
This integrated landscape makes Singapore a critical launchpad to Asia-Pacific markets, providing global firms with a high-trust base for clinical trials and regional distribution. With a thriving venture capital scene and a highly skilled workforce, the ecosystem continues to pioneer breakthroughs in oncology, immunology and chronic disease management.
Featured Editorial
Universities
Singapore has six autonomous universities. Leading institutions include the National University of Singapore (NUS) and Nanyang Technological University (NTU). NUS hosts the Yong Loo Lin School of Medicine and Duke-NUS Medical School.
Government Funding
Since 2000, the Singapore government has invested over $2 billion into developing its biomedical research capabilities, notably through the creation of the biomedical research campus hub Biopolis and initiatives that helped attract top scientists and international companies.
VC Funding
Venture financings in Singapore have seen significant increases in the past decade, from a one to 12-fold increase from 2012 and 2023. Leading life science investors from the US, Europe and other parts of Asia have established a presence in Singapore alongside ClavystBio in the past few years. Accelerator Life Science Partners made its first investment in the region, co-leading a $16 million Series A round with ClavystBio in Automera, a startup developing novel targeted protein degradation approaches.
Life Science Firms
Biomanufacturing operations are concentrated in facilities such as Tuas Biomedical Park, which hosts global companies including Merck, Novartis, Pfizer, Wyeth, Genentech and GSK.
Big Pharma Presence
Prominent global pharmaceutical and biotech firms such as Novartis, Eli Lilly, Siemens and Abbott have established research and development operations in Singapore. In manufacturing, Tuas Biomedical Park hosts players like Merck, Novartis, Pfizer, Wyeth, Genentech and GSK.
Big Medtech Presence
Singapore has more than 50 medtech multinational corporations (MNCs) and more than 400 medtech and digital health start-ups.
Active Clinical Studies
There are currently over 885 clinical studies underway in Singapore.
